Compare AKAN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAN | GOVX |
|---|---|---|
| Founded | 2021 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | 2021 | 1996 |
| Metric | AKAN | GOVX |
|---|---|---|
| Price | $0.87 | $0.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 165.2K | 104.6K |
| Earning Date | 09-30-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.42 | $0.16 |
| 52 Week High | $78.90 | $1,344.25 |
| Indicator | AKAN | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 24.26 | 9.66 |
| Support Level | $0.80 | N/A |
| Resistance Level | $1.11 | $4.60 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 13.11 | 0.46 |
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.